Minerva Neurosciences, Inc. (NERV)
| Market Cap | 50.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -48.99M |
| Shares Out | 5.34M |
| EPS (ttm) | -1.19 |
| PE Ratio | n/a |
| Forward PE | 11.21 |
| Dividend | n/a |
| Ex-Dividend Date | Jun 21, 2022 |
| Volume | 290,108 |
| Open | 9.20 |
| Previous Close | 9.10 |
| Day's Range | 8.71 - 9.80 |
| 52-Week Range | 2.51 - 16.08 |
| Beta | -0.22 |
| Analysts | Buy |
| Price Target | 37.06 (+292.6%) |
| Earnings Date | Nov 7, 2022 |
About NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for NERV stock is "Buy." The 12-month stock price forecast is 37.06, which is an increase of 292.58% from the latest price.
News
NERV, FAZE: The Top 5 Short Squeeze Stocks This Week
Source: Shutterstock Short squeeze stocks are still worth keeping track of as traders look for potential gains this week! This has us turning to Fintel and its Short Squeeze Leaderboard for the latest s...
NRBO, FAZE: The Top 5 Short Squeeze Stocks to Watch This Week
Source: Alextype/Shutterstock.com Traders continue to show interest in short squeeze stocks this week as they seek out likely targets to push higher. This has us checking out Fintel's Short Squeeze Lead...
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
BURLINGTON, Mass., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...
Billionaire Steven Cohen Just Made a Big Bet on Minerva Neurosciences (NERV) Stock
Shares of Minerva Neurosciences (NASDAQ: NERV ) are soaring higher by over 70% following a purchase by Steve Cohen's Point72 Asset Management and the company's submission of a new drug application (NDA...
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up
Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in ...
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...
Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher
Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement ...
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022 Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Thir...
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022 Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter ...
Minerva Outlines Next Steps For US Application For Schizophrenia Candidate
Minerva Neurosciences Inc (NASDAQ: NERV) received the official meeting minutes from the Type C meeting with the FDA regarding the development of roluperidone for negative symptoms in schizophrenia. The ...
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a ...
Company to Host Webcast Wednesday, April 13, 2022 at 11am ET Company to Host Webcast Wednesday, April 13, 2022 at 11am ET
Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centr...
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
Trial Results Confirm the Potential of Roluperidone To Treat Negative Symptoms and Improve Everyday Functioning in Patients with Schizophrenia Trial Results Confirm the Potential of Roluperidone To Trea...
Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
Company to Host Conference Call Today at 8:30 a.m. ET
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as ...
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
Management to Host Conference Call Management to Host Conference Call
Minerva Neurosciences Announces Promotion of Geoff Race to President
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA
Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation. Re...
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commerci...
Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration
Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of -47.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...
Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for
Minerva Neurosciences (NERV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.